[
  {
    "ts": null,
    "headline": "Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera",
    "summary": "Earlier in December, Regeneron Pharmaceuticals reported encouraging Phase 1/2 data for its investigational multiple myeloma therapy Lynozyfic™ (linvoseltamab), advanced a broad early-stage program in newly diagnosed patients, and entered a global collaboration with Tessera Therapeutics to develop TSRA-196, an in vivo “Gene Writing” candidate for alpha-1 antitrypsin deficiency. These updates highlight Regeneron’s push to extend its oncology footprint and expand into genetic medicines,...",
    "url": "https://finnhub.io/api/news?id=ae344339883003975bbacaa794106fbf4a3f610d89f764f6d75e7deb16663f9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765800435,
      "headline": "Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera",
      "id": 137792761,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Earlier in December, Regeneron Pharmaceuticals reported encouraging Phase 1/2 data for its investigational multiple myeloma therapy Lynozyfic™ (linvoseltamab), advanced a broad early-stage program in newly diagnosed patients, and entered a global collaboration with Tessera Therapeutics to develop TSRA-196, an in vivo “Gene Writing” candidate for alpha-1 antitrypsin deficiency. These updates highlight Regeneron’s push to extend its oncology footprint and expand into genetic medicines,...",
      "url": "https://finnhub.io/api/news?id=ae344339883003975bbacaa794106fbf4a3f610d89f764f6d75e7deb16663f9f"
    }
  }
]